PRQR - Why ProQR Therapeutics Is Crashing Today
Shares of ProQR Therapeutics (NASDAQ: PRQR) , a clinical-stage biopharmaceutical company, are sinking in response to lousy clinical trial results. The company's lead candidate, sepofarsen, failed to meet the primary endpoint in the Illuminate study. The stock was down 75.1% as of 12:08 p.m. ET on Friday.
ProQR didn't have anything good to say about the long-anticipated results that investors had hoped would support the company's first new drug application. Sepofarsen failed to improve visual acuity for patients with CEP290-mediated Leber congenital amaurosis 10 (LCA10), the primary endpoint of the study. It even failed to meet secondary endpoints.
Image source: Getty Images.
For further details see:
Why ProQR Therapeutics Is Crashing Today